Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Liver Cancer > Volume 17(1); 2017 > Article
Case Report A Case of Achieving Complete Remission with Combination of Sorafenib and Tegafur in Patients with Hepatocellular Carcinoma with Progression of Disease after Sorafenib Therapy
Sang Youn Hwang1, Seon-Mi Lee1, Jung Woo Im1, Ki Jeong Jeon1, Sang Bu Ahn2, Jin-Young Park2, Cheol-Won Choi3, Kwang-Mo Yang3
Journal of Liver Cancer 2017;17(1):88-93
DOI: https://doi.org/10.17998/jlc.17.1.88
Published online: March 31, 2017
1Departments of Internal Medicine, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea
2Departments of Radiology,Dongnam Institute of Radiological & Medical Sciences, Busan, Korea
3Departments of Radiation Oncology, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea
Corresponding author:  Sang Youn Hwang,
Email: mongmani@daum.net
  • 1,766 Views
  • 9 Download
  • 0 Crossref
  • 0 Scopus

Sorafenib is the only approved targeted agent as the first line systemic therapy for treatment of advanced hepatocellular carcinoma (HCC). However, the improvement of survival duration under 3 months is far from clinical satisfactory and most patients experience disease progression within 6 months after sorafenib therapy. Unfortunately, second line systemic therapy after treatment failure of sorafenib was not established and there were no clear guidelines for salvage treatment modalities. Recently, studies suggests that combination of sorafenib and single cytotoxic agent can be relatively effective and safe strategy that achieves promising rates of local and systemic control in advanced HCC patients. Based on above suggestions, we herein offer our experience of a case achieved complete remission by combination therapy of sorafenib and tegafur in the patient with progressed disease after sorafenib therapy.

Related articles

JLC : Journal of Liver Cancer